Immunogenicity and Determinants of Antibody Response to the BNT162b2 mRNA Vaccine: A Longitudinal Study in a Cohort of People Living with HIV
The immunogenicity of the BNT162b2 vaccine in PLWH has been confirmed, with booster doses necessary to maintain high levels of anti-SARS-CoV-2 Spike IgG antibodies, especially in patients with comorbidities. These findings underline the importance of a personalized vaccination strategy in this population.
Authors
- Ruggero Geppini (ORCID: https://orcid.org/0000-0002-5655-8105)
- Marco Fonzo (ORCID: https://orcid.org/0000-0002-9561-0711)
- Irene Amoruso (ORCID: https://orcid.org/0000-0003-4954-5848)
- Maria Mazzitelli (ORCID: https://orcid.org/0000-0003-0263-0703)
- Anna Maria Cattelan (ORCID: https://orcid.org/0000-0003-2869-2945)
- Lolita Sasset
- Vincenzo Baldo (ORCID: https://orcid.org/0000-0001-6012-9453)
- Mascia Finco
- Chiara Bertoncello (ORCID: https://orcid.org/0000-0003-4040-8601)
- Tatjana Baldovin (ORCID: https://orcid.org/0000-0002-7375-9187)
- Andrea Miatton (ORCID: https://orcid.org/0009-0004-7909-7294)
- Davide Leoni
Institutions
- University of Padua (IT)
Publication Details
- Journal
- Vaccines
- Published
- 2024-10-16
- DOI
- https://doi.org/10.3390/vaccines12101172
- Citations
- 1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Università degli Studi di Padova